Oncolytics Biotech Inc
Oncolytics Biotech Inc. is a clinical-stage biopharmaceutical company focused on developing pelareorep, an intravenously delivered immunotherapeutic agent for cancer. The company is organized around advancing this oncology program through clinical development, manufacturing readiness, and regulatory submission activities.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2020–2025
Liiketoiminta
Osuus liikevaihdostaDevelopment of pelareorep as an intravenously delivered cancer immunotherapy.
Drug substance, fill-finish, analytical testing, and process validation activities.
Work supporting clinical trials, regulatory filings, and biomarker/translation efforts.
Asiakkaat
Oncolytics does not sell a commercial product to end consumers; its primary counterparties are clinical investigators, trial sites, contract manufacturers, regulators, and potential development partners. The company’s future customer base, if pelareorep is approved, would include oncology treatment providers and healthcare systems using the therapy in cancer care.
They use pelareorep in sponsored studies to generate efficacy and safety data.
They review clinical, manufacturing, and quality data for approval pathways.
They produce drug substance and finished product under cGMP conditions.
They may fund development or commercialize pelareorep in defined indications.
If approved, hospitals and cancer centers would administer pelareorep-based therapy.
Strategia
The company’s strategy is to advance pelareorep through clinical development, with emphasis on metastatic colorectal cancer and squamous cell carcinoma of the anal canal. A second priority is manufacturing readiness, including process validation and cGMP supply, so the program can support later-stage development and potential regulatory submission.
Clinical progress in lead tumor types is the main value driver for a single-asset biotech.
Process validation and cGMP readiness are required for regulatory submission and future supply.
Development-stage biotech programs require ongoing capital and may benefit from shared risk.
Maantiede
The company is headquartered in the United States and reports in U.S. dollars, while its operating footprint is tied to clinical development and manufacturing activities that can span multiple jurisdictions. Its geography matters mainly through trial execution, manufacturing supply chains, and regulatory pathways rather than through commercial sales concentration.
Riskit
Oncolytics faces the typical risks of a clinical-stage biotech: clinical trial failure, regulatory delay, and uncertainty around whether pelareorep can reach approval and commercialization. The company also depends on external financing and manufacturing execution, so setbacks in funding or process validation could slow or reduce development activity.
Pelareorep must show sufficient safety and efficacy in oncology trials to support approval.
Kohdistuu: Lead programs in metastatic colorectal cancer and anal canal cancer
The company expects to rely on equity or collaborations to fund operations.
Commercial readiness depends on successful cGMP production and validated processes.
Even positive clinical data must satisfy FDA and other regulators on quality and efficacy.
Kohdistuu: Submission package and approval pathway
Kirjanpito
Harkinnanvaraiset erätClinical and manufacturing vendors are often accrued based on estimates and timing of services received.
Vaikutus: Can cause quarter-to-quarter expense volatility
ATM offerings and warrant exercises affect cash, dilution, and equity balances.
Vaikutus: Changes share count and financing-related disclosures
Public-company biotech compensation often relies on equity awards.
Vaikutus: Non-cash expense affects operating loss and diluted share metrics
The company changed its functional currency to U.S. dollars effective January 1, 2026.
Vaikutus: Affects translation of foreign-currency balances and comparability
Operating leases and manufacturing commitments require judgment in recognition and disclosure.
Vaikutus: Influences liabilities and near-term cash needs
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
Onconetix, Inc.
ONCO · Pharmaceutical Preparations
Relay Therapeutics, Inc.
RLAY · Biological Products, (No Diagnostic Substances)
CG Oncology, Inc.
CGON · Biological Products, (No Diagnostic Substances)
Oncotelic Therapeutics, Inc.
OTLC · Pharmaceutical Preparations
IO Biotech, Inc.
IOBTQ · Pharmaceutical Preparations
Cardiff Oncology, Inc.
CRDF · Biological Products, (No Diagnostic Substances)
Päivitetty: 16.6.2026